Dapiprazole clinical efficiency for counteracting tropicamide 1%

Area of Science:

• Ophthalmology
• Clinical Pharmacology

Background:

• Tropicamide is commonly used for mydriasis in ophthalmological examinations.
• Mydriasis and cycloplegia induced by tropicamide can impair visual function, affecting tasks like reading.
• Reversal agents may improve patient comfort and reduce recovery time.

Purpose of the Study:

• To evaluate the clinical efficacy of dapiprazole in reversing the effects of tropicamide.
• To assess the impact of dapiprazole on pupillary size, accommodation, and intraocular pressure following tropicamide instillation.

Main Methods:

• A randomized, placebo-controlled, masked study involving 30 subjects.
• Ophthalmic examination included pupil diameter, accommodation amplitude, conjunctival injection, and intraocular pressure measurements.
• Dapiprazole was administered 30 minutes after tropicamide dilation, with measurements taken at baseline and up to 180 minutes post-dapiprazole.

Main Results:

• Dapiprazole significantly reduced pupillary recovery time compared to placebo.
• Faster recovery of accommodation was observed in eyes treated with dapiprazole.
• Return to comfortable reading ability was quicker with dapiprazole (43 min) versus without (66 min).
• Conjunctival hyperemia was a consistent side effect observed in all subjects post-dapiprazole administration.

Conclusions:

• Dapiprazole is clinically useful for reversing tropicamide-induced mydriasis and accelerating the recovery of accommodation.
• The use of dapiprazole can shorten the time for patients to regain functional vision, such as reading ability.
• Conjunctival hyperemia is a common adverse effect associated with dapiprazole use.